Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants

NCT04252300 — Phase 1, Completed, 14 participants, Bayer

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Open Label, Fixed Sequences, One-way Cross-over Study to Determine the Effects of Multiple Doses BAY1817080 (150 mg) on the Pharmacokinetics of a 5 mg Dose Rosuvastatin in Healthy Participants

Registry	NCT04252300
Status	Completed
Phase	Phase 1
Study type	Interventional; non randomized, crossover, masking: none, basic science
Enrollment	14 (Actual)
Sponsor	Bayer (Industry)
Conditions	Drug Interactions
Interventions	Rosuvastatin, Rosuvastatin + BAY1817080 (Drug)
Dates	start 2020-03-02, primary completion 2020-08-29, completion 2020-12-07, first posted 2020-02-05, last updated 2021-03-11
Locations	1 site in United States

-Summary

Researchers in this study want to learn how the study drug BAY1817080 interacts with another drug called rosuvastatin (brand name: Crestor) and affects the way the body absorbs, distributes and excretes rosuvastatin in healthy adult male and female participants (drug-drug interaction study). The study drug BAY1817080 is a new drug under development with a goal to suppress pain and chronic cough. It works by binding to and blocking proteins related to pain in the body. Rosuvastatin is an approved and marketed drug to lower high levels of "bad" cholesterol (a waxy, fat-like substance found in blood). Both drugs interact with the same proteins (molecules) in the human body, and as a result, the study drug may affect the way rosuvastatin is taken up and used by the body when applied together.

Participants in this study will be asked to visit the clinic 3 times over a period of 3 to 4 weeks. Each participant will receive rosuvastatin tablets twice with at least 11 days in between and the study drug tablets twice daily for 14 days. Blood samples will be taken from the participants to measure the blood levels of rosuvastatin.

Expand all sections · Collapse all

+Detailed description

The primary objective of the study is to investigate the influence of multiple doses of BAY1817080 on the pharmacokinetics of rosuvastatin given concomitantly. Secondary objective is to investigate the safety of BAY1817080.

+Arms and interventions

Arm	Type	Interventions	Description
Healthy subjects_Period 1	Experimental	Drug: Rosuvastatin	Healthy adults from USA receive a single dose of rosuvastatin (interaction drug) in Period 1.
Healthy subjects_Period 2	Experimental	Drug: Rosuvastatin + BAY1817080	The healthy adults from Period 1 receive both rosuvastatin + BAY1817080 in Period 2.

Rosuvastatin (Drug), also known as Crestor®: Single dose of 5 mg rosuvastatin is administered as tablet orally on Day 1 of Period 1 (total length = 5 days).
Rosuvastatin + BAY1817080 (Drug), also known as P2X3 receptor antagonist;, Crestor®: A single dose of 5 mg rosuvastatin tablets is administered on Day 8 of Period 2 (total length = 15 days). BAY1817080 is administered as tablets twice daily on Days 1 to 14 of Period 2.

+Outcome measures

Primary outcomes

Maximum plasma concentration of rosuvastatin without concomitant administration of BAY1817080 (Cmax) [Predose and up to 15 hours after drug on Day 1, 0 and 12 hours on Day 2, 0 hours on Day 3, 4 and 5 of Period 1]
Maximum plasma concentration of rosuvastatin after concomitant administration of BAY1817080 (Cmax1) [Predose and up to 15 hours after rosuvastatin on Day 8, 0 and 12 hours on Day 9, 0 hour on Days 10, 11, 12, 13, 14 and 15 of Period 2]
Area under the concentration-time curve of rosuvastatin without concomitant administration of BAY1817080 (AUC) [Predose and up to 15 hours after drug on Day 1, 0 and 12 hours on Day 2, 0 hours on Day 3, 4 and 5 of Period 1]
Area under the concentration-time curve of rosuvastatin after concomitant administration of BAY1817080 (AUC1) [Predose and up to 15 hours after rosuvastatin on Day 8, 0 and 12 hours on Day 9, 0 hour on Days 10, 11, 12, 13, 14 and 15 of Period 2]

Secondary outcomes

Number of participants with treatment-emergent adverse events (TEAEs) [Up to 10 weeks]
Severity of treatment-emergent adverse events [Up to 10 weeks]

+Eligibility

Sex: All, ages: 18 Years to 55 Years, accepts healthy volunteers

Inclusion Criteria:

* Participant is healthy as determined by the investigator
* White or Black race
* Body mass index (BMI) ≥ 18.0 and ≤ 30.0 kg/m² at screening
* Body weight of at least 50 kg at screening

Exclusion Criteria:

* Known or suspected allergy or hypersensitivity to BAY1817080, rosuvastatin or any of their excipients
* Asian race
* Contraindications to rosuvastatin
* Any use of systemic or topically active medication or herbal remedies, prescription or non-prescription, within 1 week prior to the first study intervention administration or during the study until follow-up (occasional use of ibuprofen is permissible)
* History of or positive COVID-19 test or contact with COVID-19 positive subject in past 4 weeks

+Locations (1)

Facility	City	Country	Status
Covance Clinical Research Unit, Inc.	Daytona Beach, Florida	United States